127 related articles for article (PubMed ID: 26916292)
1. Extended anticoagulation and mortality in venous thromboembolism. A meta-analysis of six randomized trials.
Bova C; Bianco A; Mascaro V; Nobile CG
Thromb Res; 2016 Mar; 139():22-8. PubMed ID: 26916292
[TBL] [Abstract][Full Text] [Related]
2. Anticoagulation after venous thromboembolism. Deciding on the optimal duration.
Eichinger S
Hamostaseologie; 2013 Aug; 33(3):211-7. PubMed ID: 23719863
[TBL] [Abstract][Full Text] [Related]
3. Gender differences in cancer patients with acute venous thromboembolism.
Martín-Martos F; Trujillo-Santos J; Barrón M; Vela J; Javier Marchena P; Braester A; Hij A; Hernández-Blasco L; Verhamme P; Manuel M;
Thromb Res; 2015 Feb; 135 Suppl 1():S12-5. PubMed ID: 25903526
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: A network meta-analysis.
Sobieraj DM; Coleman CI; Pasupuleti V; Deshpande A; Kaw R; Hernandez AV
Thromb Res; 2015 May; 135(5):888-96. PubMed ID: 25795564
[TBL] [Abstract][Full Text] [Related]
5. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism.
Douketis J; Tosetto A; Marcucci M; Baglin T; Cushman M; Eichinger S; Palareti G; Poli D; Tait RC; Iorio A
Ann Intern Med; 2010 Oct; 153(8):523-31. PubMed ID: 20956709
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary embolism risk stratification by European Society of Cardiology is associated with recurrent venous thromboembolism: Findings from a long-term follow-up study.
Zhang S; Zhai Z; Yang Y; Zhu J; Kuang T; Xie W; Yang S; Liu F; Gong J; Shen YH; Wang C
Int J Cardiol; 2016 Jan; 202():275-81. PubMed ID: 26408837
[TBL] [Abstract][Full Text] [Related]
7. Shorter or longer anticoagulation to prevent recurrent venous thromboembolism: systematic review and meta-analysis.
Lopes LC; Eikelboom J; Spencer FA; Akl EA; Kearon C; Neumann I; Schulman S; Bhatnagar N; Guyatt G
BMJ Open; 2014 Jul; 4(7):e005674. PubMed ID: 24996916
[TBL] [Abstract][Full Text] [Related]
8. The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK.
Jugrin AV; Ustyugova A; Urbich M; Lamotte M; Sunderland T
Thromb Haemost; 2015 Oct; 114(4):778-92. PubMed ID: 26272227
[TBL] [Abstract][Full Text] [Related]
9. Activated partial thromboplastin time monitoring in patients receiving unfractionated heparin for venous thromboembolism in relation to clinical outcomes.
Vardi M; Laor A; Bitterman H
Thromb Haemost; 2009 Nov; 102(5):879-86. PubMed ID: 19888523
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes of Incidental Venous Thromboembolism in Cancer and Noncancer Patients: The SWIss Venous ThromboEmbolism Registry (SWIVTER).
Spirk D; Sebastian T; Barco S; Banyai M; Beer JH; Mazzolai L; Baldi T; Aujesky D; Hayoz D; Engelberger RP; Kaeslin T; Korte W; Escher R; Husmann M; Blondon M; Kucher N
Thromb Haemost; 2021 May; 121(5):641-649. PubMed ID: 33202448
[TBL] [Abstract][Full Text] [Related]
11. Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
Wu C; Alotaibi GS; Alsaleh K; Linkins LA; McMurtry MS
Thromb Res; 2015 Feb; 135(2):243-8. PubMed ID: 25488466
[TBL] [Abstract][Full Text] [Related]
12. Timing of recurrent venous thromboembolism early after the index event: a meta-analysis of randomized controlled trials.
Limone BL; Hernandez AV; Michalak D; Bookhart BK; Coleman CI
Thromb Res; 2013 Oct; 132(4):420-6. PubMed ID: 24011386
[TBL] [Abstract][Full Text] [Related]
13. Tinzaparin and VKA use in patients with cancer associated venous thromboembolism: a retrospective cohort study.
Noel-Savina E; Sanchez O; Descourt R; André M; Leroyer C; Meyer G; Couturaud F
Thromb Res; 2015 Jan; 135(1):78-83. PubMed ID: 25466839
[TBL] [Abstract][Full Text] [Related]
14. [Optimal duration of anticoagulation of venous thromboembolism].
Savina EN; Couturaud F
J Mal Vasc; 2011 Dec; 36 Suppl 1():S28-32. PubMed ID: 22177766
[TBL] [Abstract][Full Text] [Related]
15. Treatment of venous thromboembolism.
Wells PS; Forgie MA; Rodger MA
JAMA; 2014 Feb; 311(7):717-28. PubMed ID: 24549552
[TBL] [Abstract][Full Text] [Related]
16. Comparison of All-Cause Mortality Following VTE Treatment Between Propensity Score-Adjusted Observational Studies and Matched Randomized Controlled Trials: Meta-Epidemiologic Study.
Coscia C; Jaureguizar A; Quezada CA; Muriel A; Monreal M; Villén T; Barbero E; Chiluiza D; Yusen RD; Jimenez D
Chest; 2019 Apr; 155(4):689-698. PubMed ID: 30961834
[TBL] [Abstract][Full Text] [Related]
17. Long-term anticoagulation for venous thromboembolism: duration of treatment and management of warfarin therapy.
Kearon C
Clin Chest Med; 2010 Dec; 31(4):719-30. PubMed ID: 21047578
[TBL] [Abstract][Full Text] [Related]
18. Assessing the risk of recurrent venous thromboembolism--a practical approach.
Fahrni J; Husmann M; Gretener SB; Keo HH
Vasc Health Risk Manag; 2015; 11():451-9. PubMed ID: 26316770
[TBL] [Abstract][Full Text] [Related]
19. Resuming Anticoagulation Following Hospitalization for Gastrointestinal Bleeding Is Associated with Reduced Thromboembolic Events and Improved Mortality: Results from a Systematic Review and Meta-Analysis.
Tapaskar N; Pang A; Werner DA; Sengupta N
Dig Dis Sci; 2021 Feb; 66(2):554-566. PubMed ID: 32279174
[TBL] [Abstract][Full Text] [Related]
20. Association between anticoagulant treatment duration and risk of venous thromboembolism recurrence and bleeding in clinical practice.
Kaatz S; Fu AC; AbuDagga A; LaMori J; Bookhart BK; Damaraju CV; Tan H; Schein J; Nutescu E
Thromb Res; 2014 Oct; 134(4):807-13. PubMed ID: 25127013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
